Overview
Paradox Biosciences develops next-generation small-molecule therapeutics targeting synaptic plasticity pathways for the treatment of treatment-resistant depression and PTSD.
More in Neuropharmaceuticals
Latest industry news
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Tether Evo Takes On One of BCI's Hardest Engineering Problems
2026-09-19 · Research
Neuroprosthesis Breakthrough Enables Paralyzed Patients to Speak and Move Simultaneously
2026-09-18 · Research
Neurofeedback Systems Market Projected to Reach $2.95 Billion by 2035 as Clinical and Consumer Demand Converges
2026-09-17 · Industry
Company details
Category
💊 Neuropharmaceuticals
Location
San Diego, CA
Funding
Series A — $42M
Website
paradoxbiosciences.comListed
2026-08-31
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →